Claims for Patent: 10,182,984

Summary for Patent: 10,182,984

Title:	Targeted interferons demonstrate potent apoptotic and anti-tumor activities
Abstract:	Novel chimeric moieties that show significant efficacy against cancers are provided. In certain embodiments the chimeric moieties comprise a targeting moiety attached to an interferon. In certain embodiments, the chimeric moieties comprise fusion proteins where an antibody that specifically binds to a cancer marker is fused to interferon alpha (IFN-.alpha.) or interferon beta (IFN-.beta.).
Inventor(s):	Morrison; Sherie L. (Los Angeles, CA), Huang; Tzu-Hsuan (Libertyville, IL), Xuan; Caiyun (Newton, MA)
Assignee:	The Regents of the University of California (Oakland, CA)
Application Number:	15/359,456
Patent Claims:	1. A method of inhibiting growth and/or proliferation of a rituximab-resistant cancer cell, said method comprising contacting said cancer cell with a chimeric construct comprising an interferon attached to an antibody that binds to a tumor-associated antigen, wherein said antibody is attached to said interferon by a linker where the amino acid sequence of said linker consists of the sequence SGGGGS (SEQ ID NO:81) or AEAAAKEAAAKAGS (SEQ ID NO:82), wherein said construct when contacted to said rituximab-resistant cancer cell results in the killing or inhibition of growth or proliferation of said cancer cell. 2. The method of claim 1, wherein said cancer cell is a metastatic cell. 3. The method of claim 1, wherein said cancer cell is in a solid tumor. 4. The method of claim 1, wherein said cancer cell is a breast cancer cell. 5. The method of claim 1, wherein said cancer cell is a B cell lymphoma. 6. The method of claim 1, wherein said cancer cell is cell produced by a cancer selected from the group consisting of a B cell lymphoma, lung cancer, a bronchus cancer, a colorectal cancer, a prostate cancer, a breast cancer, a pancreas cancer, a stomach cancer, an ovarian cancer, a urinary bladder cancer, a brain or central nervous system cancer, a peripheral nervous system cancer, an esophageal cancer, a cervical cancer, a melanoma, a uterine or endometrial cancer, a cancer of the oral cavity or pharynx, a liver cancer, a kidney cancer, a biliary tract cancer, a small bowel or appendix cancer, a salivary gland cancer, a thyroid gland cancer, a adrenal gland cancer, an osteosarcoma, a chondrosarcoma, a liposarcoma, a testes cancer, and a malignant fibrous histiocytoma. 7. The method of claim 1, wherein: said contacting comprises systemically administering said chimeric moiety to a mammal; or said contacting comprises administering said chimeric moiety directly into a tumor site; or said contacting comprises intravenous administration of said chimeric moiety. 8. The method of claim 1, wherein said cancer cell is a cancer cell in a human. 9. The method of claim 1, wherein said cancer cell is a cancer cell in a non-human mammal. 10. The method of claim 1, wherein said interferon is an interferon alpha. 11. The method of claim 1, wherein said interferon is an interferon beta. 12. The method of claim 1, wherein said construct is a recombinantly expressed fusion protein. 13. The method of claim 1, wherein said antibody specifically binds a marker selected from the group consisting of CD20, HER3, HER2/neu, MUC-1, G250, mesothelin, gp100, tyrosinase, and MAGE. 14. The method of claim 1, wherein said antibody is an antibody that binds CD20. 15. The method of claim 14, wherein said antibody that comprises the complementarity determining regions (CDRs) of anti-CD20 (rituximab). 16. The method of claim 14, wherein said antibody comprises the variable regions of anti-CD20 (rituximab). 17. The method of claim 1, wherein said antibody is an antibody that binds HER2.

Details for Patent 10,182,984

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2027-09-21
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2027-09-21